We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Lumosa Therapeutics

News List

Lumosa Therapeutics Partners with Camargo Pharmaceutical Services in the Development of Naldebain(R) prnasia
August 29, 2017
TAIPEI, Taiwan, China and CINCINNATI, Aug. 28, 2017 /PRNewswire/ -- Lumosa Therapeutics Co., Ltd. ("Lumosa"), a Taipei-based biopharmaceutical company developing innovative therapies focused on the treatment of neurological and inflammatory disease
Enrollment of first human subject for Lumosa Therapeutics’ LT3001 trial pharmaasia
August 15, 2017
The first human subject was dosed with LT3001 in California, USA on 28 July 2017, with the trial to evaluate the safety and pharmacokinetics of LT3001 expected to be completed in early 2018.